Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) includes patients with hepatic steatosis and at least one of five cardiometabolic risk factors. Xanthine oxidase (XO) represents a treatment target for MASLD. We aimed to evaluate the effect of two xanthine oxidase inhibitors, allopuri...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shargi, Amani, El Kholy, Amal A., Adel, Abdulmoneim, Hassany, Mohamed, Shaheen, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669273/
https://www.ncbi.nlm.nih.gov/pubmed/38002074
http://dx.doi.org/10.3390/biomedicines11113074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669273/
https://www.ncbi.nlm.nih.gov/pubmed/38002074
http://dx.doi.org/10.3390/biomedicines11113074

Ejemplares similares